Hyponatremia in acute decompensated heart failure: Mechanisms, prognosis, and treatment options

Clinical Cardiology

Volumn 33, Issue 11, 2010, Pages 666-671

  Jao, Geoffrey T ^a   Chiong, Jun R ^b  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONIVAPTAN; DEMECLOCYCLINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LITHIUM; LOOP DIURETIC AGENT; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; SODIUM; SODIUM CHLORIDE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST;

ACUTE DECOMPENSATED HEART FAILURE; ACUTE HEART FAILURE; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG WITHDRAWAL; HEART FAILURE; HEART VENTRICLE FUNCTION; HUMAN; HYPONATREMIA; HYPOTENSION; LOADING DRUG DOSE; NEPHROTOXICITY; POLYURIA; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SODIUM BLOOD LEVEL; THIRST; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ARGININE VASOPRESSIN; BENZAZEPINES; BIOLOGICAL MARKERS; FLUID THERAPY; HEART FAILURE; HORMONE ANTAGONISTS; HUMANS; HYPONATREMIA; RECEPTORS, VASOPRESSIN; RENIN-ANGIOTENSIN SYSTEM; SODIUM; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION;

EID: 78649673076     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20822     Document Type: Review

References (39)

1. Upadhyay A, Jaber BL, Madias NE,. Incidence and prevalence of hyponatremia. Am J Med 2006; 119 (7 suppl 1): S30-S35.
2. Gheorghiade M, Abraham WT, et al.,; for OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcome in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007; 28: 980-988.
3. Gheorghiade M, Rossi J, et al., Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med 2007; 167: 1998-2005.
4. Rossi J, Bayram M, Udelson JE, et al., Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care 2007; 9: 82-86.
5. Robertson GL., Antidiuretic hormone: normal and disordered function. Endocrinol Metab Clin North Am 2001; 30: 671-694.
6. Wong LL, Verbalis JG., Systemic diseases associated with diseases of water homeostasis. Endocrinol Metab Clin North Am 2002; 31: 121-140.
7. Anderson RJ, Chang HM, Kluge R, et al., Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985; 102: 164-168.
8. Schrier RW, Berl T., Nonosmolar factors affecting renal water excretion (first of 2 parts). N Engl J Med 1975; 292: 81-88.
9. Schrier RW, Berl T., Nonosmolar factors affecting renal water excretion (second of 2 parts). N Engl J Med 1975; 292: 141-145.
10. Sica DA,. Sodium and water retention in heart failure and diuretic therapy: basic mechanisms. Cleve Clin J Med 2006; 73 (suppl 2): S2-S7.
11. Sica DA,. Hyponatremia and heart failure-treatment considerations. Congest Heart Fail 2006; 12: 55-60.
12. Oren RM,. Hyponatremia in congestive heart failure. Am J Cardiol 2005; 95: 2B-7B.
13. Schrier RW, Ecder T,. Unifying hypothesis of body fluid volume regulation: implications for cardiac failure and cirrhosis. Mt Sinai J Med 2001; 68: 350-361.
14. Abramow M, Cogan E,. Clinical aspects and pathophysiology of diuretic-induced hyponatremia. Adv Nephrol Necker Hosp 1984; 13: 1-28.
15. Sonnenblick M, Friedlander Y, Rosin AJ,. Diuretic-induced severe hyponatremia review and analysis of 129 reported patients. Chest 1993; 103: 601-606.
16. Miller WL, Skouri HN,. Chronic systolic heart failure, guideline-directed medical therapy, and systemic hypotension-less pressure but maybe more risk (does this clinical scenario need more discussion?). J Card Fail 2009; 15: 101-107.
17. Androgué HJ, Madias NE., Hyponatremia. N Engl J Med 2000; 342: 1581-1589.
18. Soupart A, Decaux G,. Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications. Clin Nephrol 1996; 46: 149-169.
19. Renneboog B, Musch W, Vandemergel X, et al., Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006; 119: 71.e1-71.e8.
20. Schrier RW, Gross P, Gheorghiade M, et al., Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112.
21. Lee WH, Packer M., Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986; 73: 257-267.
22. Lee D, Austin PC, Rouleau JL, et al., Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 290: 2581-2587.
23. Teuteberg JJ, Lewis EF, Nohria A, et al., Characteristics of patients who die with heart failure and a low ejection fraction in the new millennium. J Card Fail 2006; 12: 47-53.
24. Klein L, O'Connor CM, Leimberger JD, et al,; for OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005; 111: 2454-2460.
25. Rusinaru D, Buiciuc O, Leborgne L, et al., Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction. Am J Cardiol 2009; 103: 405-410.
26. Tribouilloy C, Buiciuc O, Rusinaru D, et al., Long-term outcome after a first episode of heart failure: a prospective 7-year study. Int J Cardiol 2010; 140: 309-314.
27. Milo-Cotter O, Cotter G, Weatherley BD, et al., Hyponatraemia in acute heart failure is a marker of increased mortality but not when associated with hyperglycaemia. Eur J Heart Fail 2008; 10: 196-200.
28. Sterns RH, Nigwekar SU, Hix JK,. The treatment of hyponatremia. Semin Nephrol 2009; 29: 282-299.
29. Sterns RH, Cappuccio JD, Silver SM, et al., Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994; 1552-1530.
30. Licata G, Di Pasquale P, Parrinello G, et al., Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J 2003; 145: 459-466.
31. Gheorghiade M, Niazi I, Ouyang J, et al., Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107: 2690-2696.
32. Gheorghiade M, Konstam MA, Burnett JC Jr, et al,; for Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-1343.
33. Konstam MA, Gheorghiade M, Burnett JC Jr, et al,; for Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331.
34. Pang PS, Konstam MA, Krasa HB, et al,; for Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of tolvaptan on dyspnea relief from the EVEREST trials. Eur Heart J 2009; 30: 2233-2240.
35. Blair JE, Khan S, Konstam MA, et al,; for EVEREST Investigators. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. Eur Heart J 2009; 30: 1666-1673.
36. Udelson JE, Orlandi C, Ouyang J, et al., Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic heart failure: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 1540-1545.
37. Zeltser D, Rosansky S, van Rensburg H, et al,; Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007; 27: 447-457.
38. Udelson JE, Smith WB, Hendrix GH, et al., Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417-2423.
39. Goldsmith SR, Elkayam U, Haught WH, et al., Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail 2008;: 14: 641-647.